Mingchao Kang

Company: Ambrx

Job title: Group Lead, Head Technology Platform

Seminars:

Panel Discussion: What is the Best Modality & Delivery Approach to PRR-Pathway Targeting? 2:30 pm

Discussing safety profiles, dosing and scheduling considerations, therapeutic window Dissecting drug design approach for systemic and intratumoral Understanding possible regulatory considerations Mechanisms of action that are leading to strong efficacy Enhancing administration and delivery of therapies for safe and effective clinical outcomes Systemic delivery technologies vs intra-tumoral delivery technologiesRead more

day: Day Two

Site-Specific TLR7 Agonist Antibody-Drug Conjugates as Next Generation ADCs 1:30 pm

Presenting on the site-specific TLR7a ADC developed by EuCODE platform with an expanded genetic code Reviewing how protein medicinal chemistry enables fine-tuning of TLR7a ADC to balance potency and safety in preclinical studies Demonstrating how Ambrx’s TLR7a ADCs elicit strong anti-tumor responses as single-agent as well as in combination therapiesRead more

day: Day Two